Nicotine Effects on Endophenotypes of Schizophrenia

University Hospital Bonn (UKB)

Status: Completed

Conditions: Schizophrenia

Treatments: Drug: Placebo patch; Drug: Transdermal nicotine patch

Study type: Interventional

Funder types: Other

Identifiers

NCT01315002

2008-001362-90 (EudraCT Number)

NICSZ001

Details and patient eligibility

About

The purpose of this study is to test the effects of nicotine on cognition with the following schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected first-degree relatives of schizophrenia patients and healthy controls receive transdermal nicotine in a double-blind, placebo-controlled, crossover study.

Full description

Convergent findings suggest that an altered neuronal nicotinic acetylcholine receptor system may contribute to the pathophysiology of schizophrenia. Nicotine consumption through cigarette smoking might represent a form of self-medication in schizophrenia as nicotine reduces cognitive and physiological deficits in schizophrenia. The present study aims to investigate how nicotine affects attentional and executive schizophrenia endophenotypes and how genetic polymorphisms relating to the cholinergic system might play a role in inter-individual differences in the magnitude of nicotine effects.

Schizophrenia patients, first-degree relatives of schizophrenia patients as well as healthy controls will receive transdermal nicotine in a double-blind, placebo-controlled, crossover study and will be assessed with prepulse inhibition, antisaccades, the continuous performance test, spatial working memory and a verbal memory task. Subjects will be overnight-abstinent smokers and non-smokers. However, the investigators will particularly test non-smokers in order to eliminate confounding effects of nicotine withdrawal and reinstatement.

Main hypotheses:

Schizophrenia patients will perform worse than matched controls in all cognitive tests (validating our endophenotypes). Nicotine administration will enhance cognitive performance in overnight-abstinent smokers. Improvement of cognitive performance in smokers with schizophrenia will be stronger than in control smokers. Improvement of cognitive performance in smoking first-degree relatives of schizophrenia patients will be stronger than in control smokers. Nicotine administration will affect cognitive functioning in non-smoking subjects. Nicotine administration will improve cognitive functioning in non-smoking schizophrenia patients. The effects of nicotine in non-smoking subjects are stronger in those subjects who are cognitively more impaired (i.e. performing below the median of the respective group).

The present research contributes to the issue whether nicotinic cholinergic receptor agonists may have therapeutic value in the treatment of cognition in schizophrenia.

Enrollment: 121 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients:

• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) diagnosis of schizophrenia
• age 18-55 years old
• able to provide informed consent
• treated with antipsychotic medications at a stable dose for at least 6 weeks
• normal or corrected to normal vision
• smokers (Fagerström Test for Nicotine Dependence > 4)
• non-smokers (< 100 cigarettes/lifetime, not having smoked in the past year)

Controls:

• age 18-55 years old
• able to provide informed consent
• normal or corrected to normal vision
• smokers (Fagerström Test for Nicotine Dependence > 4)
• non-smokers (< 100 cigarettes/lifetime, not having smoked in the past year)

Unaffected First-Degree Relatives of Schizophrenia Patients:

• same inclusion criteria as controls plus
• having an adult first-degree relative (sibling, parent, child) with a DSM IV diagnosis of schizophrenia

Exclusion criteria

Patients:

• substance dependence
• clinical instability
• changes in medication in the last 6 weeks
• anticholinergic medication
• untreated hypertension
• cardiovascular disease
• insulin-dependent diabetes mellitus
• phaeochromocytoma
• uncontrolled hyperthyroidism
• renal or hepatic impairment
• central nervous system disease
• pulmonary disease
• generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis, urticaria, etc.)
• gastric or intestinal ulcer
• hypersensitivity to nicotine
• allergy to patches
• women: pregnancy, lactation

Controls:

• substance dependence
• having a first-, second-, or third-degree relative with a psychotic disorder
• DSM IV Axis I disorder
• anticholinergic medication
• untreated hypertension
• cardiovascular disease
• insulin-dependent diabetes mellitus
• phaeochromocytoma
• uncontrolled hyperthyroidism
• renal or hepatic impairment
• central nervous system disease
• pulmonary disease
• generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis, urticaria, etc.)
• gastric or intestinal ulcer
• hypersensitivity to nicotine
• allergy to patches
• women: pregnancy, lactation

Unaffected First-Degree Relatives of Schizophrenia Patients:

• same exclusion criteria as controls

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

121 participants in 2 patient groups, including a placebo group

Nicotine Patch

Active Comparator group

Description:

Transdermal nicotine patch

Treatment:

Drug: Transdermal nicotine patch

Placebo patch

Placebo Comparator group

Description:

Placebo patch

Treatment:

Drug: Placebo patch